Morningstar

Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease

Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease Anti-microtubule binding region-tau antibody ...
MarketWatch

Bristol Myers Gets FDA Fast-Track Designation for BMS-986446 in Alzheimer's

Bristol Myers Squibb has won Food and Drug Administration fast-track designation for its BMS-986446 drug candidate in Alzheimer's disease. Bristol Myers on Wednesday said BMS-986446 is a potential ...
Insider Monkey

Bristol Myers Squibb’s Alzheimer’s Drug, BMS-986446, Granted FDA Fast Track Status

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 5 years. On October 2, Bristol Myers Squibb announced a development in its Alzheimer’s program: its experimental ...
Seeking Alpha

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of ...

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the potential of anti ...